A new breakthrough in weight loss medication could disrupt the current market, offering a needle-free alternative that challenges big pharma’s grip.
Story Highlights
- Eli Lilly’s obesity pill helps maintain weight loss post-injection.
- The FDA has granted a priority review voucher for the pill.
- The pill could serve as a needle-free option, reshaping the GLP-1 market.
- Potential market impact as Novo Nordisk aims to launch a similar product first.
Eli Lilly’s Innovative Approach to Obesity Treatment
On December 18, 2025, Eli Lilly announced that their obesity pill, orforglipron, demonstrated effectiveness in maintaining weight loss after patients transitioned from injections like Wegovy and Zepbound.
This development comes amid a late-stage trial, prompting Eli Lilly to seek FDA approval for their daily GLP-1 pill. The pill offers a promising alternative to weekly injections, which many patients find burdensome.
This breakthrough positions Eli Lilly to potentially disrupt the existing market, currently dominated by Novo Nordisk. Their oral obesity treatment is poised to enter the market ahead of Eli Lilly’s offering, but the latter’s priority review voucher from the FDA could expedite its availability.
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound https://t.co/4aUnOYO7W0
— CNBC (@CNBC) December 18, 2025
Trial Results and Implications for the Market
The phase three trial involved over 300 patients who had previously used Wegovy or Zepbound for 72 weeks. Transitioning to Eli Lilly’s pill resulted in significant weight maintenance compared to a placebo.
Patients switching from Wegovy regained only about 2 pounds, while those from Zepbound regained approximately 11 pounds by the trial’s end. These results highlight the pill’s potential as a maintenance treatment in the lucrative GLP-1 market.
The pill’s safety profile aligns with previous studies, with mild-to-moderate gastrointestinal side effects being the most common. Notably, no liver safety issues were reported, providing further confidence in the product’s viability.
Future Prospects and Market Dynamics
Eli Lilly’s pill works similarly to existing treatments by targeting the GLP-1 hormone to suppress appetite and regulate blood sugar levels. Unlike peptide-based medications, this pill is more easily absorbed and does not necessitate dietary restrictions, offering patients a more convenient option.
Goldman Sachs analysts foresee pills capturing a 24% share of the global weight loss drug market by 2030, with Eli Lilly commanding a significant portion.
The competition between Eli Lilly and Novo Nordisk is set to intensify, with implications for market dynamics and consumer choice. As both companies vie for dominance, patients stand to benefit from a broader array of treatment options.
